Pharmaceutical lobby

[1] According to the Center for Public Integrity, from January 2005 through June 2006 alone, the pharmaceutical industry spent approximately $182 million on federal lobbying in the United States.

[5][failed verification] The lobby's influence in securing the passage of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 was considered a major and controversial[according to whom?]

[5][7] According to Marcia Angell, former editor-in-chief of the New England Journal of Medicine, "The United States is the only advanced country that permits the pharmaceutical industry to charge exactly what the market will bear.

[9][10] In 2021, during the height of COVID-19, vaccine makers increased lobbying and public-relations efforts to oppose a proposal that would temporarily waive their patents in Germany, Japan and other countries.

Pharmaceutical industry representatives have been lobbying members of Congress to pressure the Biden administration to reverse its support of the waiver, arguing that the patents protect its innovations.